The Full Wiki

More info on L-838,417

L-838,417: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

L-838,417
Systematic (IUPAC) name
3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-

6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]- 1,2,4-triazolo[4,3-b]pyridazine

Identifiers
CAS number 286456-42-6
ATC code  ?
PubChem 9908880
Chemical data
Formula C 19H19F2N7O 
Mol. mass 399.397 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

L-838,417 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. The compound was developed by Merck, Sharp and Dohme.

L-838,417 is a subtype-selective GABAA agonist, acting as a partial agonist at α2, α3 and α5 subtypes, but as an antagonist at the α1 subtype, and has little affinity for the α4 or α6 subtypes.[1] This gives it selective anxiolytic effects, which are mediated mainly by α2 and α3 subtypes, but with little sedative or amnestic effects as these effects are mediated by α1.[2][3] Some sedation might still be expected due to its activity at the α5 subtype, which can also cause sedation, however no sedative effects were seen in animal studies even at high doses, suggesting that L-838,417 is primarily acting at α2 and α3 subtypes with the α5 subtype of lesser importance.[4][5]

As might be predicted from its binding profile, L-838,417 substitutes for the anxiolytic benzodiazepine chlordiazepoxide in animals, but not for the hypnotic imidazopyridine drug zolpidem.[6][7] The synthesis of L-838,417 and similar compounds was described in 2005 in the Journal of Medicinal Chemistry.[8]

References

  1. ^ McKernan RM, Rosahl TW, Reynolds DS, et al. (2000). "Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype". Nat. Neurosci. 3 (6): 587–92. doi:10.1038/75761. PMID 10816315. http://dx.doi.org/10.1038/75761.  
  2. ^ Atack JR (2005). "The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics". Expert Opin Investig Drugs 14 (5): 601–18. doi:10.1517/13543784.14.5.601. PMID 15926867. http://www.expertopin.com/doi/abs/10.1517/13543784.14.5.601.  
  3. ^ Morris HV, Dawson GR, Reynolds DS, Atack JR, Stephens DN (2006). "Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm". Eur. J. Neurosci. 23 (9): 2495–504. doi:10.1111/j.1460-9568.2006.04775.x. PMID 16706856. http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0953-816X&date=2006&volume=23&issue=9&spage=2495.  
  4. ^ Mathiasen LS, Rodgers RJ, Mirza NR (2007). "Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test". Behav Pharmacol 18 (3): 191–203. doi:10.1097/FBP.0b013e32814fcdd4. PMID 17426483. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00008877-200705000-00003.  
  5. ^ Ujfalussy B, Kiss T, Orbán G, Hoffmann WE, Erdi P, Hajós M (2007). "Pharmacological and computational analysis of alpha-subunit preferential GABA(A) positive allosteric modulators on the rat septo-hippocampal activity". Neuropharmacology 52 (3): 733–43. doi:10.1016/j.neuropharm.2006.09.022. PMID 17113111. http://linkinghub.elsevier.com/retrieve/pii/S0028-3908(06)00337-6.  
  6. ^ Mirza NR, Rodgers RJ, Mathiasen LS (2006). "Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination". J. Pharmacol. Exp. Ther. 316 (3): 1291–9. doi:10.1124/jpet.105.094003. PMID 16339395. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16339395.  
  7. ^ Mathiasen L, Mirza NR (2005). "A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test". Psychopharmacology (Berl.) 182 (4): 475–84. doi:10.1007/s00213-005-0119-z. PMID 16133136. http://dx.doi.org/10.1007/s00213-005-0119-z.  
  8. ^ Carling RW, Madin A, Guiblin A, et al. (2005). "7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models". J. Med. Chem. 48 (23): 7089–92. doi:10.1021/jm058034a. PMID 16279764. http://dx.doi.org/10.1021/jm058034a.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message